Koh, SciClone Pharmaceuticals, personal communication, 2000 May 5). TA1 has been granted
orphan drug status for the treatment of chronic hepatitis B, hepatocellular carcinoma, and DiGeorge's syndrome with immune defects.[1] (Di George's syndrome is a congenital birth defect that leads to hypoplasia or aplasia of the thymus and parathyroid glands, cardiac defects, and immune system dysfunction.